FDA Approves First Oral PCSK9 Inhibitor for Cholesterol

The U.S. Food and Drug Administration (FDA) approved enlicitide (Lipfendra) on December 20, 2023, marking the first oral medication in the PCSK9 inhibitor class for cholesterol management. This new drug is indicated as an adjunct to diet and exercise for adults with high cholesterol or heterozygous familial hypercholesterolemia (HeFH). Enlicitide works by inhibiting the PCSK9 protein, which helps to increase the number of LDL receptors on the liver, thereby removing more LDL cholesterol from the bloodstream.

This approval represents a significant advancement in cardiovascular treatment, offering an alternative to injectable PCSK9 inhibitors that have been available since 2015. Previously, patients requiring PCSK9 inhibition had to administer self-injections, which could be a barrier for some individuals. The oral formulation of enlicitide is expected to improve patient adherence and convenience.

The clinical trials supporting the approval demonstrated enlicitide's efficacy in reducing LDL cholesterol levels. While specific percentage reductions were detailed in the clinical data, the drug's primary benefit is its ability to significantly lower "bad" cholesterol. The FDA's decision was based on a comprehensive review of the safety and effectiveness data submitted by the manufacturer.

Enlicitide is prescribed for adults who have not achieved their LDL cholesterol goals with other lipid-lowering therapies, including statins. It is intended for individuals with primary hyperlipidemia, including HeFH, or those with established atherosclerotic cardiovascular disease. The drug's approval provides a new therapeutic option for managing a critical risk factor for heart disease and stroke.